Rigel Pharmaceuticals Stock Forecast
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
RIGL analyst consensus
Consensus (5 analysts)
none
Avg. price target
$63.00+31.28%
- Strong buy 0
- Buy 3
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering Rigel Pharmaceuticals (2026-10-08), 3 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $63.00, with a high estimate of $85.00 and a low estimate of $43.00. The average target implies upside of 31.3% from the current price of $47.99.
The spread between the highest and lowest targets is 97.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RIGL.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 60% |
| Hold | 2 | 40% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $43.00 | -10.40% |
| Average target | $63.00 | +31.28% |
| High target | $85.00 | +77.12% |